Urogen Pharma (NASDAQ:URGN) Shares Down 6.1% – Should You Sell?

Urogen Pharma (NASDAQ:URGN) dropped 6.1% during mid-day trading on Tuesday . The stock traded as low as $26.87 and last traded at $26.72. Approximately 242,123 shares changed hands during trading, a decline of 83% from the average daily volume of 1,435,098 shares. The stock had previously closed at $28.46.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on URGN shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Wednesday, October 8th. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Urogen Pharma in a research report on Monday, October 27th. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Urogen Pharma in a research report on Monday, October 27th. Finally, Piper Sandler assumed coverage on shares of Urogen Pharma in a research report on Monday, August 18th. They set an “overweight” rating and a $36.00 price objective on the stock. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Urogen Pharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Urogen Pharma Price Performance

The company has a market cap of $1.14 billion, a PE ratio of -7.02 and a beta of 1.21. The business’s fifty day simple moving average is $21.26 and its two-hundred day simple moving average is $17.09.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.03. The firm had revenue of $27.48 million for the quarter, compared to analyst estimates of $34.09 million. Urogen Pharma had a negative net margin of 170.59% and a negative return on equity of 97,487.15%. As a group, analysts predict that Urogen Pharma will post -3.12 EPS for the current year.

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 10,000 shares of the company’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $25.00, for a total value of $250,000.00. Following the completion of the transaction, the insider directly owned 139,025 shares in the company, valued at approximately $3,475,625. This represents a 6.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jason Drew Smith sold 1,520 shares of the firm’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $19.11, for a total transaction of $29,047.20. Following the completion of the transaction, the general counsel directly owned 43,305 shares in the company, valued at $827,558.55. This represents a 3.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 14,594 shares of company stock worth $332,813. Company insiders own 4.70% of the company’s stock.

Institutional Trading of Urogen Pharma

Institutional investors have recently modified their holdings of the company. Paradigm Biocapital Advisors LP bought a new stake in shares of Urogen Pharma during the third quarter valued at approximately $84,111,000. RA Capital Management L.P. bought a new stake in Urogen Pharma during the first quarter worth $35,461,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Urogen Pharma by 216.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock valued at $48,227,000 after purchasing an additional 2,983,368 shares during the last quarter. Soleus Capital Management L.P. acquired a new stake in Urogen Pharma during the 2nd quarter worth approximately $29,934,000. Finally, SG Americas Securities LLC grew its holdings in shares of Urogen Pharma by 607.1% during the 2nd quarter. SG Americas Securities LLC now owns 1,149,081 shares of the company’s stock worth $15,742,000 after purchasing an additional 986,567 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.